Neoadjuvant Therapy: Current Landscape and Future Horizons for ER-Positive/HER2-Negative and Triple-Negative Early...

Area of Science:

• Oncology
• Medical Research

Background:

• Breast cancer treatment strategies vary significantly between luminal and triple-negative subtypes.
• Neoadjuvant chemotherapy is a traditional approach for triple-negative breast cancer.
• Endocrine therapy, including aromatase inhibitors, is established for certain luminal breast cancers.

Purpose of the Study:

• To review current treatment paradigms for luminal and triple-negative breast cancer.
• To highlight the emerging role of immunotherapy in triple-negative breast cancer.
• To discuss challenges and future directions in optimizing breast cancer therapy.

Main Methods:

• Literature review of recent clinical evidence and treatment guidelines.
• Analysis of treatment outcomes for different breast cancer subtypes.
• Discussion of emerging therapeutic strategies and predictive factor research.

Main Results:

• Immunotherapy, combined with chemotherapy, shows significant impact in triple-negative breast cancer.
• Endocrine therapy, such as aromatase inhibitors, is effective for postmenopausal luminal A tumors.
• The role of CDK4/6 inhibitors in the neoadjuvant setting for luminal cancers requires further investigation.

Conclusions:

• Personalized treatment approaches are essential for optimizing breast cancer management.
• Understanding subtype-specific characteristics is crucial for effective therapy selection.
• Ongoing research is necessary to identify predictive factors and refine treatment strategies, particularly for luminal breast cancers.